Search Result

Results for "

ovarian

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (3) AAK1 (1) ADAMTS (1) ADC Antibody (12) ADC Payload (10) Adrenergic Receptor (3) Akt (36) Aldehyde Dehydrogenase (ALDH) (3) Amine N-methyltransferase (1) AMPK (2) Amyloid-β (1) Anaplastic lymphoma kinase (ALK) (2) Angiotensin Receptor (3) Angiotensin-converting Enzyme (ACE) (3) Antibiotic (8) Antibody-Drug Conjugates (ADCs) (8) Antifolate (4) Apelin Receptor (APJ) (2) Apoptosis (188) Arf Family GTPase (1) Arginase (2) Aryl Hydrocarbon Receptor (1) ASK1 (2) Atg8/LC3 (2) ATM/ATR (3) Aurora Kinase (7) Autophagy (29) Bacterial (19) Bcl-2 Family (19) BCL6 (1) Bcr-Abl (3) BCRP (2) Beta-secretase (2) Biochemical Assay Reagents (17) BMI1 (2) Bradykinin Receptor (1) c-Fms (1) c-Kit (1) c-Myc (8) C-type Lectin-like Receptors (CTLRs) (1) Cadherin (3) Calcium Channel (11) Carbonic Anhydrase (4) Casein Kinase (2) Caspase (17) CD3 (4) CD47 (1) CDK (37) Ceramidase (1) Checkpoint Kinase (Chk) (4) Cholinesterase (ChE) (1) CMV (2) Collagen (1) Complement System (1) COX (12) CTLA-4 (1) Cuproptosis (1) CXCR (5) Cyclophilin (1) Cytochrome P450 (20) Dengue Virus (1) Deubiquitinase (3) Disulfidptosis (2) DNA Alkylator/Crosslinker (8) DNA/RNA Synthesis (27) Drug Derivative (23) Drug Intermediate (7) Drug Isomer (3) Drug Metabolite (5) Drug-Linker Conjugates for ADC (8) DYRK (1) E1/E2/E3 Enzyme (4) Early 2 Factor (E2F) (2) EGFR (13) Endogenous Metabolite (21) Endonuclease (7) Endothelin Receptor (1) Environmental Pollutants (5) Ephrin Receptor (3) Epigenetic Reader Domain (5) ERK (17) Estrogen Receptor/ERR (17) FAK (9) FAP (2) Fc Receptor (FcR) (1) Ferroptosis (17) FGFR (2) FLT3 (7) Fluorescent Dye (6) Folate Receptor (FR) (11) Fungal (9) FXR (5) G Protein-coupled Receptor Kinase (GRK) (1) GABA Receptor (4) Galectin (1) Glucosylceramide Synthase (GCS) (2) GLUT (3) Glutaminase (7) Glycosidase (4) Glycosyltransferase (1) GnRH Receptor (11) GPR68 (1) GSK-3 (1) HCV (1) HDAC (8) Heme Oxygenase (HO) (2) Hexokinase (1) HIF/HIF Prolyl-Hydroxylase (4) Histone Acetyltransferase (2) Histone Demethylase (7) Histone Methyltransferase (11) HIV (3) HMG-CoA Reductase (HMGCR) (1) HSP (8) HSV (3) IAP (5) IFNAR (3) IGF-1R (2) IKZF Family (1) Indoleamine 2,3-Dioxygenase (IDO) (3) Influenza Virus (3) Integrin (7) Interleukin Related (12) IRE1 (2) Isotope-Labeled Compounds (19) JAK (2) JNK (5) Keap1-Nrf2 (2) Kinesin (7) Lactate Dehydrogenase (3) LAG-3 (2) Ligands for Target Protein for PROTAC (1) LILRB (1) Lipase (1) Liposome (3) Lipoxygenase (2) LPL Receptor (4) LXR (2) Macrophage migration inhibitory factor (MIF) (1) MAGL (1) MDM-2/p53 (13) MEK (5) Melanocortin Receptor (1) Mesothelin (1) METTL3 (3) MicroRNA (3) Microtubule/Tubulin (18) Mitochondrial Metabolism (5) Mitosis (3) Mixed Lineage Kinase (1) MMP (15) Molecular Glues (4) Monoamine Oxidase (2) Mps1 (1) mTOR (18) Mucin (7) Na+/K+ ATPase (1) nAChR (1) NAMPT (1) Necroptosis (5) NEDD8-activating Enzyme (2) NEKs (2) NF-κB (14) NO Synthase (2) Notch (7) Nucleoside Antimetabolite/Analog (2) P-glycoprotein (6) P2X Receptor (2) p38 MAPK (10) p62 (2) PAI-1 (1) PAK (3) Paraptosis (1) Parasite (8) PARP (31) PD-1/PD-L1 (9) PDGFR (2) PDI (2) Peptide-Drug Conjugates (PDCs) (2) PERK (3) Phosphatase (5) Phospholipase (2) PI3K (18) Pim (1) PKC (2) Polo-like Kinase (PLK) (3) Poly(ADP-ribose) Glycohydrolase (PARG) (1) Potassium Channel (5) PPAR (12) Progesterone Receptor (7) Prostaglandin Receptor (3) PROTACs (22) Proteasome (3) PTEN (2) Pyroptosis (1) RAD51 (1) Radionuclide-Drug Conjugates (RDCs) (2) Raf (5) RAR/RXR (1) Ras (7) Reactive Oxygen Species (ROS) (30) Reference Standards (41) RET (1) Reverse Transcriptase (3) Ribosomal S6 Kinase (RSK) (1) RIP kinase (2) ROCK (1) ROR (3) ROS Kinase (1) Salt-inducible Kinase (SIK) (4) SARS-CoV (5) Ser/Thr Protease (1) SHMT (1) Sigma Receptor (1) Sirtuin (4) SOD (6) Sodium Channel (3) Sodium Phosphate Cotransporter (1) Src (5) STAT (11) STING (1) Survivin (2) SWI/SNF Complex (1) Syk (2) TAM Receptor (2) TGF-beta/Smad (7) TGF-β Receptor (4) Thymidylate Synthase (3) Tie (1) TMV (1) TNF Receptor (7) Toll-like Receptor (TLR) (8) Topoisomerase (18) Transferrin Receptor (1) Transglutaminase (2) Transmembrane Glycoprotein (4) Trk Receptor (1) TROP2 (2) TRP Channel (9) TrxR (1) Tyrosinase (1) VEGFR (11) Virus Protease (1) Wee1 (7) Wnt (7) YAP (5) YB-1 (1) β-catenin (3) γ-secretase (1)
By Research Areas:	Cancer (657) Cardiovascular Disease (41) Endocrinology (51) Infection (50) Inflammation/Immunology (96) Metabolic Disease (46) Neurological Disease (45)
Click Chemistry:	DBCO (5) Tetrazine (1) Alkynes (8)
Oligonucleotides:	Aptamers (2) Phospholipids (4) Polymers (3) Antisense Oligonucleotides (2) Cholesterol (1)

715

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

GMP Molecules

Nutlin-3a 65+ Cited Publications Rebemadlin	MDM-2/p53 E1/E2/E3 Enzyme Autophagy Apoptosis	Cancer
Nutlin-3a (Rebemadlin), an active enantiomer of Nutlin-3, is a potent murine double minute (MDM2) inhibitor (IC₅₀=90 nM). Nutlin-3a inhibits MDM2-p53 interactions and stabilizes the p53 protein, and induces cell autophagy and apoptosis. Nutlin-3a has the potential for the study of TP53 wild-type ovarian carcinomas .

Calycosin 20+ Cited Publications Cyclosin	Apoptosis	Neurological Disease Cancer
Calycosin is a compound that can be isolated from Radix Astragali. Calycosin has strong antioxidant, anti-inflammatory and apoptosis-modulating effects. Calycosin can be used for the research of ovarian cancer and breast cancer .

Mirvetuximab 2 Publications Verification M9346A	Antifolate ADC Antibody	Cancer
Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research .

Solitomab AMG 110	CD3	Cancer
Solitomab (AMG 110) is a bispecific anti-CD3 and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer .

SU056 2 Publications Verification	YB-1	Cancer
SU056 is a YB-1 inhibitor. SU056 induces cell-cycle arrest, apoptosis, and inhibits cell migration in ovarian cancer cells. SU056 interacts with YB-1 and inhibits and its associated downstream proteins and pathways. SU056 can enhance the cytotoxic effects of Paclitaxel (HY-B0015) .

SKLB325 2 Publications Verification	Histone Demethylase Apoptosis	Cancer
SKLB325 is a Jumonji domain-containing 6 (JMJD6) inhibitor with a binding affinity (K_D) value of 0.755 μM, and the IC₅₀ value of 0.7797 μM. SKLB325 exhibits antitumor effects on ovarian cancer in vivo and in vitro. SKLB325 induces apoptosis . SKLB325 exhibits remarkable antitumor efficacy in renal cell carcinoma (RCC) .

Cofetuzumab PF-06523435; hu24	ADC Antibody RET PERK ROR	Cancer
Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. The expression system of Cofetuzumab is typically CHO (Chinese hamster ovary) cells. Cofetuzumab downregulates PTK7 expression, modulates its downstream signaling pathways, and inhibits tumor sphere formation of ovarian cancer cells. Cofetuzumab can be used to synthesize the ADC molecule Cofetuzumab pelidotin (HY-P99829). Cofetuzumab is applicable to the research of tumors such as ovarian cancer .

11-Beta-hydroxyandrostenedione 4-Androsten-11β-ol-3,17-dione	Endogenous Metabolite 11β-HSD	Endocrinology
11-Beta-hydroxyandrostenedione (4-Androsten-11β-ol-3,17-dione) is a steroid mainly found in the the adrenal origin (11β-hydroxylase is present in adrenal tissue, but absent in ovarian tissue). 11-Beta-hydroxyandrostenedione is a 11β-hydroxysteroid dehydrogenase (11βHSD) isozymes inhibitor. As 4-androstenedione increases, measuring plasma 11-Beta-hydroxyandrostenedione can distinguish the adrenal or ovarian origin of hyperandrogenism .

Trastuzumab duocarmazine (vic)-Trastuzumab duocarmazine	Antibody-Drug Conjugates (ADCs)	Cancer
Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas .

Mirvetuximab (powder) 2 Publications Verification M9346A (powder)	Antifolate ADC Antibody	Cancer
Mirvetuximab (M9346A) (powder) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab (powder) is the antibody moiety of folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research .

Imalumab BAX69; Anti-Human MIF Recombinant Antibody	Macrophage migration inhibitory factor (MIF)	Cancer
Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer .

Verubulin MPC 6827	Microtubule/Tubulin	Cancer
Verubulin (MPC-6827) is a highly potent and broad-spectrum microtubule blocker. Verubulin has antitumor activity against breast cancer, melanoma, and ovarian cancer. Verubulin can be used in non-small cell lung cancer research .

(R)-Ketorolac 1 Publications Verification (+)-Ketorolac	Ras	Cancer
(R)-Ketorolac is an orally active Cdc42 and Rac1 inhibitor. (R)-Ketorolac inhibits GTPase. (R)-Ketorolac alters ovarian cancer cell behaviors critical for invasion and metastasis. (R)-Ketorolac ameliorates cancer-associated cachexia .

RA-9	Deubiquitinase Apoptosis	Cancer
RA-9 is a potent and selective proteasome-associated deubiquitinating enzymes (DUBs) inhibitor with favorable toxicity profile and anticancer activity. RA-9 blocks ubiquitin-dependent protein degradation without impacting 20S proteasome proteolytic activity. RA-9 selectively induces onset of apoptosis in ovarian cancer cell lines and primary cultures derived from donors. RA-9 induces endoplasmic reticulum (ER)-stress responses in ovarian cancer cells .

Clofibric acid Chlorofibrinic acid	PPAR Bacterial SOD	Infection Metabolic Disease Cancer
Clofibric acid (Chlorofibrinic acid) is an orally active PPARα agonist. Clofibric acid inhibits the fimbriation of *Escherichia coli. Clofibric acid increases SOD* activity. Clofibric acid lowers blood lipids and prevents experimental pyelonephritis. Clofibric acid has anticancer activity against ovarian cancer. Clofibric acid is also a herbicide. Clofibric acid is used in ovarian cancer, liver cancer, obesity, and urinary tract infection research .

Cetrorelix 1 Publications Verification SB-75	GnRH Receptor	Endocrinology
Cetrorelix is a potent gonadotrophin-releasing hormone (GnRH) antagonist. Cetrorelix inhibits the endogenous luteinizing hormone surge during ovarian stimulation. Cetrorelix reduces cyclophosphamide induced ovarian follicular destruction in mice .

ABT-510 1 Publications Verification	Apoptosis	Inflammation/Immunology Cancer
ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

ALDH1A inhibitor 673A 2 Publications Verification ALDH1Ai 673A	Aldehyde Dehydrogenase (ALDH) Mitochondrial Metabolism Necroptosis	Cancer
ALDH1A inhibitor 673A is an ALDH1A inhibitor with IC₅₀s of 246 nM (ALDH1A1), 230 nM (ALDH1A2), 348 nM (ALDH1A3), respectively. ALDH1A inhibitor 673A has little or no inhibitory effect on other ALDH family members. ALDH1A inhibitor 673A induces necroptotic ovarian cancer stem-like cells (CSCs) death. ALDH1A inhibitor 673A induces DNA double stand breaks in cancer cells. ALDH1A inhibitor 673A can be used for the study of ovarian cancer .

NSC756093 SU093	Pim Apoptosis	Cancer
NSC756093 (SU093) is a GBP1:PIM1 interaction inhibitor. NSC756093 binds to GBP1-PIM1 with a K_d of 38 nM. NSC756093 suppresses proliferation, reduces migration, induces G1 phase cell-cycle arrest, and increases apoptotic cell death in ovarian cancer cells. NSC756093 reduces cellular proteasomal activity, induces accumulation of ubiquitinated proteins, and restrains tumor progression and lung metastasis in murine ovarian cancer xenograft models. NSC756093 increases sensitivity of prostate cancer cells to Docetaxel (HY-B0011) and sensitizes GBP1-overexpressing ovarian cancer cells to Paclitaxel (HY-B0015). NSC756093 can be used for the research of prostate cancer and ovarian cancer .

Ran-IN-1	Arf Family GTPase Apoptosis	Cancer
Ran-IN-1 is a specific inhibitor of Ran GTPase. Ran-IN-1 selectively induces cytotoxicity and apoptosis in aneuploid ovarian cancer cells and also inhibits DNA repair. Ran-IN-1 exhibits antitumor activity and is useful for research on tumors such as epithelial ovarian cancer .

ABT-510 acetate 1 Publications Verification	Apoptosis	Inflammation/Immunology Cancer
ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

MR22	Salt-inducible Kinase (SIK)	Cancer
MR22 is a potent pan-SIK (salt-inducible kinase) inhibitor. MR22 no longer exhibits activity on STE group kinases and displays excellent selectivity in a representative kinase panel. MR22-dependent SIK inhibition led to centrosome dissociation and subsequent cell-cycle arrest in ovarian cancer cells .

SIC-19	Salt-inducible Kinase (SIK)	Cancer
SIC-19 is a SIK2 inhibitor and promotes SIK2 protein degradation via the ubiquitination pathway. SIC-19 inhibits cancer cell growth and sensitizes cells to PARP inhibitors (Such as Olaparib (HY-10162)), as well as in ovarian cancer organoids and xenograft models .

LAG-3 Hit II	LAG-3	Cancer
LAG-3 Hit II is a LAG-3 inhibitor with a K_D of 4.32  μM. LAG-3 Hit II can be used for cancers like ovarian cancer, colon adenocarcinoma and melanoma research .

Sulazepam	GABA Receptor	Inflammation/Immunology
Sulazepam, a benzodiazepine, is a selective ovarian cancer G protein-coupled receptor (OGR1) agonist. Sulazepam has anticonvulsive action and has the potential for airway hyperresponsiveness (AHR) research .

KIF18A-IN-13	Kinesin Microtubule/Tubulin	Cancer
KIF18A-IN-13 (Compound 16) is an effective and orally active inhibitor of KIF18A with anticancer activity in vivo. KIF18A-IN-13 can be utilized for research in ovarian cancer .

MAGL-IN-1 1 Publications Verification	MAGL	Cancer
MAGL-IN-1 is a potent, selective, reversible and competitive inhibitor of MAGL, with an IC₅₀ of 80 nM. MAGL-IN-1 exhibits anti-proliferative effects against human breast, colorectal, and ovarian cancer cells. MAGL-IN-1 blocks MAGL in cell-based as well as in vivo assays .

ReACp53 scrambled peptide TFA	MDM-2/p53	Cancer
ReACp53 scrambled peptide TFA is a negative control for ReACp53 (HY-P0121). ReACp53 scrambled peptide can be used in the study of ovarian cancer .

LP-184	Drug Derivative DNA Alkylator/Crosslinker	Cancer
LP-184 (compound 6), an acylfulvene analog, inhibits tumor growth. LP-184 has potent anti-cancer activity in the ovarian, colon, prostate and pancreatic cell lines. (patent WO2007019308A2).

Trabectedin derivative 2	Drug Derivative	Cancer
Trabectedin derivative 2 (compound PL-12) is a trabectedin derivative that can be used in research on ovarian cancer, gastric cancer, and breast cancer .

PLK1-IN-11	Polo-like Kinase (PLK)	Cancer
PLK1-IN-11 (Cluster 4, 16953209) is a PLK1 inhibitor, with IC₅₀ of 1 μM. PLK1-IN-11 can be used in research on a variety of cancers, including pancreatic, ovarian, breast, and non-small cell lung carcinoma .

TG53	Glutaminase Integrin FAK Src	Cancer
TG53 is a potent inhibitor of tissue transglutaminase (TG2) and fibronectin (FN) protein-protein interaction. TG53 inhibits formation of a complex with integrin β1 and activation of FAK and c-Src during SKOV3 cell attachment onto FN. TG53 can be used for ovarian cancer research .

PROTAC TG2 degrader-2	PROTACs Glutaminase	Cancer
PROTAC TG2 degrader-2 (compound 7) is a selective, competitive degrader targeting Transglutaminase 2 (TG2), with K_d > 100 μM. PROTAC TG2 degrader-2 inhibits the cell migration and decreases the level of TG2 in ovarian cancer cells. PROTAC TG2 degrader-2 can be used for ovarian cancer study .

WEE1-IN-8	Wee1	Cancer
WEE1-IN-8 (Compound 55) is a selective WEE1 inhibitor, with an IC₅₀ of 0.98 nM. WEE1-IN-8 (Compound 55) can be used for the research of Pancreatic cancer, Ovarian cancer, Colorectal cancer, Uterine serous carcinoma, etc .

ReACp53 scrambled peptide	MDM-2/p53	Cancer
ReACp53 scrambled peptide is a negative control for ReACp53 (HY-P0121). ReACp53 scrambled peptide can be used in the study of ovarian cancer .

Idetrexed trisodium BGC 945 trisodium; ONX 0801 trisodium; CB 300945 trisodium	Thymidylate Synthase	Cancer
Idetrexed (ONX 0801) trisodium is a thymidylate synthase (TS) inhibitor with a K_i of 1.2 nM. Idetrexed trisodium can be specifically transported into α-folate receptor (α-FR)-overexpressing tumors, such as ovarian cancer .

(S)-Acelarin (S)-NUC-1031; Fosgemcitabine palabenamide	Others	Cancer
(S)-Acelarin ((S)-NUC-1031) is an anti-cancer agent. (S)-Acelarin inhibits the growth of various cancer cells. (S)-Acelarin can be used for the study of solid tumors (e.g., pancreatic cancer, BTC, ovarian cancer) and hematological malignancies .

PARP1-IN-45	PARP BCRP	Cancer
PARP1-IN-45 (Compound 15) is a PARP1 inhibitor with an IC₅₀ of 17  nM. PARP1-IN-45 effectively stimulates ATPase activity of ABCG2. PARP1-IN-45 can be used for cancers like ovarian cancer research .

Ferruginoside C	Glycosidase	Cancer
Ferruginoside C is a phenylethanoid. Ferruginoside C can be isolated from V. leiocarpum. Ferruginoside C shows potent alpha-glucosidase inhibitory activity with an IC₅₀ of 19.93 μM. Ferruginoside C shows antioxidant activities. Ferruginoside C can be used in the research of cervical cancer, ovarian cancer, and colon cancer .

Avutometinib potassium Ro 5126766 potassium; CH5126766 potassium	Raf MEK	Cancer
Avutometinib (CH5126766) (potassium) is a RAF/MEK clamp that potently inhibits RAF/MEK kinase activity and induces dominant negative RAF-MEK complexes preventing phosphorylation of MEK by ARAF, BRAF and CRAF. Avutometinib (potassium) shows anti-proliferative potency across tumor cell lines carrying KRAS mutations including PDAC cell lines. Avutometinib (potassium) induces tumor inhibition and increases survival in a KRAS/p53 pancreatic cancer mouse model. Avutometinib (potassium) is promising for research of low-grade-serous-ovarian-carcinoma (LGSOC), ovarian cancer and pancreatic ductal adenocarcinoma (PDAC) .

N-Acetylgalactosaminyltransferase 14 GALNT14	Endogenous Metabolite	Cancer
N-Acetylgalactosaminyltransferase 14 (GALNT14) is a mucin-type glycosylating enzyme polypeptide that promotes the migration of ovarian cancer by modifying mucin 13 (MUC13). GALNT14 can regulate the O-glycosylation and stability of MUC13, thereby mediating the malignant behavior of ovarian cancer cells .

Enloplatin	Drug Derivative	Cancer
Enloplatin is a carboplatin analog, and can be used for study of ovarian cancer .

Igovomab	Transmembrane Glycoprotein	Cancer
Igovomab is a monoclonal antibody for imaging. Igovomab can be used for ovarian cancer research .

Chx-HT	Apoptosis	Cancer
Chx-HT has an anti-proliferation activity and promotes apoptosis on ovarian cancer cells .

IVHD-valtrate	Apoptosis	Cancer
IVHD-valtrate, an active Valeriana jatamansi derivative, is against human ovarian cancer cells in vitro and in vivo. IVHD-valtrate induces cancer cells apoptosis and arrests the ovarian cancer cells in the G2/M phase. IVHD-valtrate has the potential to be a novel chemotherapeutic agent for the human ovarian cancer research .

Telapristone acetate CDB-4124	Progesterone Receptor Apoptosis PARP CDK	Metabolic Disease Cancer
Telapristone acetate (CDB-4124) is a potent progesterone receptor (PR) modulator. Telapristone acetate inhibits the proliferation of ovarian cancer cells by inducing cell cycle arrest and apoptosis. Telapristone effectively inhibits the occurrence and development of spontaneous and chemically induced mammary tumors in rats. Telapristone acetate can be used for breast and ovarian cancer research .

Cat. No.	상품명

HY-L173

Anti-Ovarian Cancer Compound Library

2,817 compounds

Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer.

MCE designs a unique collection of 2,817 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.

Cat. No.	상품명	Type

HY-121608

Lumiflavin 1 Publications Verification Lumiflavine	Fluorescent Dyes
Lumiflavin (Lumiflavine), a riboflavine analog, causes significant inhibition of riboflavine uptake. Lumiflavin can effectively reduce the riboflavin enrichment in cancer stem-like cells (CSCs) and sensitize the effect of cisplatin Diamminedichloroplatinum (DDP) on CSCs. Lumiflavin is promising for research of ovarian cancer .

HY-114491

Rineterkib

Fluorescent Dyes

Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF .

HY-D2452

Cy3-Cisplatin 1 Publications Verification	Fluorescent Dyes
Cy3-Cisplatin is a Cyanine 3 fluorescent dye CY3 (HY-D0822) labled Cisplatin (HY-17394). Cy3-Cisplatin can be used for drug delivery, fluorescent labeling, cell imaging and tracking .

HY-107614G

1-Oleoyl lysophosphatidic acid sodium

1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium

Fluorescent Dyes

1-Oleoyl lysophosphatidic acid sodium (GMP) is the GMP-grade form of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). GMP-grade small molecules serve as auxiliary reagents in cell therapy. 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid signaling molecule. 1-Oleoyl lysophosphatidic acid sodium inhibits lysoPLD-catalyzed hydrolysis of lysophosphatidylcholine and FS-3. 1-Oleoyl lysophosphatidic acid sodium activates LPA₁ and LPA₂, thereby triggering calcium mobilization, NFATc1 translocation, Rho/ROCK activation, Smad2/3 phosphorylation and c-Fos expression. 1-Oleoyl lysophosphatidic acid sodium induces anxiety-like, depression-like and hypoactivity phenotypes, regulates osteoclast cytoskeleton and viability, reduces osteoclast bone resorptive activity, and drives mesenchymal stem cell differentiation into myofibroblast-like cells. 1-Oleoyl lysophosphatidic acid sodium stimulates the secretion of transforming growth factor-β1 and stromal cell-derived factor-1. 1-Oleoyl lysophosphatidic acid sodium is applicable to research related to anxiety, depression and ovarian cancer .

HY-D3432

WazaGaY-1	Fluorescent Dyes
WazaGaY-1 is an aza-BODIPY derivative, functions as a NIR-I/NIR-II fluorescent contrast agent. WazaGaY-1 undergoes internalization into tumor cells predominantly via clathrin-coated pits. WazaGaY-1 can be used for the research of glioblastoma, ovarian carcinoma and melanoma (Ex/Em = 685/820 nm) .

HY-D3186

HMRef-βGal

Fluorescent Dyes

HMRef-βGal is a fluorescent probe and a substrate responsive to β-galactosidase (β-galactosidase) (Ex/Em=498 nm/505-600 nm). After being cleaved by β-galactosidase, HMRef-βGal triggers significant fluorescence enhancement via intramolecular spirocyclic function regulation. HMRef-βGal generates bright fluorescence in cancer cells with elevated β-galactosidase activity, enabling visualization of tiny peritoneal metastases in mouse models. HMRef-βGal exhibits low in vitro cytotoxicity and low acute in vivo toxicity in mice. HMRef-βGal can be used for preclinical fluorescence-guided diagnosis and cytoreductive surgery of peritoneal metastases, including compatibility with real-time naked-eye detection and endoscopic imaging, as well as for studies related to peritoneal metastases of ovarian cancer .

HY-D3165

DCM-gal-CF	Fluorescent Dyes
DCM-gal-CF is a fluorescent probe containing a DCM fluorophore scaffold and a D-galactose recognition moiety. DCM-gal-CF itself shows weak fluorescence, and its fluorescence is enhanced after cleavage by β-galactosidase. DCM-gal-CF can be used to detect β-galactosidase activity .

HY-15947G

Ravoxertinib

GDC-0994

Fluorescent Dyes

Ravoxertinib GMP is Ravoxertinib (HY-15947) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ravoxertinib (GDC-0994) is an orally active ERK1/2 inhibitor. Ravoxertinib inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma .

Cat. No.	상품명	Type

HY-W011654

4-Aminophenyl-β-D-galactopyranoside, 98%

4-Aminophenyl-beta-D-galactopyranoside, 98%

Biochemical Assay Reagents

4-Aminophenyl-β-D-galactopyranoside, 98% is a highly efficient substrate for β-galactosidase. It is specifically hydrolyzed by this enzyme to release galactose and electroactive p-aminophenol. 4-Aminophenyl-β-D-galactopyranoside, 98% is widely used in colorimetric and electrochemical assays for detecting β-galactosidase activity and determining enzyme kinetics, such as in biosensing fields including cellular senescence, pathogen and contaminant detection. In addition, since β-galactosidase is often overexpressed in primary ovarian cancer, 4-Aminophenyl-β-D-galactopyranoside, 98% can also be applied to related research on primary ovarian cancer .

HY-155902

Mal-PEG5000-OH Maleimide-PEG5000-Hydroxy	Biochemical Assay Reagents
Mal-PEG5000-OH can be used as a macroinitiator to obtain amphiphilic diblock copolymers by ring-opening polymerization of LA. Nanoparticles prepared using amphiphilic block copolymers can form active drug delivery systems. Nanoparticles encapsulate Triptolide (HY-32735), which can avoid the disadvantage of Triptolide’s poor water solubility and reduce its toxicity.

HY-120967

(2S)-OMPT triethylamine, in ethanol:chloroform (1:1), 98%

Biochemical Assay Reagents

(2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98%, Lysophosphatidic acid analogue, is a LPA3 G-protein-coupled receptor agonist. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% selectively activates LPA3 G-protein-coupled receptor to trigger downstream cellular signaling events. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% induces calcium, IL-6 release in cancer cells and activates MAPK and Akt signaling pathways. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% can be used for the research of ovarian cancer .

HY-W1123936B

DBCO-PEG1000-FA

DBCO-PEG1000-Folate

Biochemical Assay Reagents

DBCO-PEG1000-FA (DBCO-PEG1000-Folate) is a multifunctional bioconjugation reagent, which is a copolymer of DBCO and Folic acid (FA) (HY-16637) and can target folate receptors (FR). Folate receptors are highly overexpressed on the surface of many cancer cells (such as lung cancer, nasopharyngeal cancer, ovarian cancer, etc.), but exhibit extremely low expression levels in normal tissues. DBCO-PEG-FA can be used for click chemistry conjugation via its DBCO terminal, and thus applies to various bioconjugation and drug delivery applications .

HY-W020958

Ru(acac)3

Tris(acetylacetonato)ruthenium (III)

Biochemical Assay Reagents

Ru (acac) 3 (Tris (acetylacetonato) ruthenium (III)) is a caspase-3 activator and Apoptosis inducer. Ru (acac) 3 exerts growth inhibitory effects on various cell lines in vitro by inhibiting DNA/RNA synthesis and inducing mild reversible S-phase cell cycle arrest. Ru (acac) 3 is commonly used in research related to ovarian cancer, osteosarcoma, cervical cancer, melanoma, and other fields .

HY-143203

18:0-18:2 PE

1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphoethanolamine

Biochemical Assay Reagents

18:0-18:2 PE is an important component of phosphatidylethanolamine (PE), involved in phospholipid metabolism and associated with diseases such as ovarian cancer. 18:0-18:2 PE in the hot processing process, its unsaturated fatty acids will degrade to form a variety of odor active compounds. 18:0-18:2 PE is mainly used in the field of food science to improve the flavor of aquatic products, as well as medical research on diseases related to phospholipid metabolism .

HY-155902A

Mal-PEG2000-OH Maleimide-PEG2000-Hydroxy	Biochemical Assay Reagents
Mal-PEG2000-OH can be used as a macroinitiator to obtain amphiphilic diblock copolymers by ring-opening polymerization of LA. Nanoparticles prepared using amphiphilic block copolymers can form active drug delivery systems. Nanoparticles encapsulate Triptolide (HY-32735), which can avoid the disadvantage of Triptolide’s poor water solubility and reduce its toxicity.

HY-W096169D

Platinum	Biochemical Assay Reagents
Platinum is a metallic element, and its complexes act as orally active anticancer agents. Platinum-based complexes used for tumors include Cisplatin (HY-17394), Carboplatin (HY-17393), and Oxaliplatin (HY-17371) .

HY-N1731

2′-Hydroxy-5′-methoxyacetophenone

Biochemical Assay Reagents

2'-Hydroxy-5'-methoxyacetophenone is an acetophenone derivative with acaricidal activities. 2'-Hydroxy-5'-methoxyacetophenone attenuates the inﬂammatory response via NF-κB signaling pathway. 2'-Hydroxy-5'-methoxyacetophenone exhibits significant inhibitory activity against α-amylase, collagenase and aldose reductase (AR) with IC₅₀s of 0.928, 3.264 and 20.046 μM, highlighting its potential in combating diabetes. 2'-Hydroxy-5'-methoxyacetophenone exhibits anti-ovarian cancer activity .

HY-107614G

1-Oleoyl lysophosphatidic acid sodium

1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium

Biochemical Assay Reagents

HY-W1123936C

DBCO-PEG2000-FA

DBCO-PEG2000-Folate

Biochemical Assay Reagents

DBCO-PEG2000-FA (DBCO-PEG2000-Folate) is a multifunctional bioconjugation reagent, which is a copolymer of DBCO and Folic acid (FA) (HY-16637) and can target folate receptors (FR). Folate receptors are highly overexpressed on the surface of many cancer cells (such as lung cancer, nasopharyngeal cancer, ovarian cancer, etc.), but exhibit extremely low expression levels in normal tissues. DBCO-PEG-FA can be used for click chemistry conjugation via its DBCO terminal, and thus applies to various bioconjugation and drug delivery applications .

HY-W1123936D

DBCO-PEG3400-FA

DBCO-PEG3400-Folate

Biochemical Assay Reagents

DBCO-PEG-FA (DBCO-PEG-Folate) (MW 3400) is a multifunctional bioconjugation reagent, which is a copolymer of DBCO and Folic acid (FA) (HY-16637) and can target folate receptors (FR). Folate receptors are highly overexpressed on the surface of many cancer cells (such as lung cancer, nasopharyngeal cancer, ovarian cancer, etc.), but exhibit extremely low expression levels in normal tissues. DBCO-PEG-FA can be used for click chemistry conjugation via its DBCO terminal, and thus applies to various bioconjugation and drug delivery applications .

HY-155902B

Mal-PEG1000-OH Maleimide-PEG1000-Hydroxy	Biochemical Assay Reagents
Mal-PEG1000-OH was used as a macroinitiator to obtain amphiphilic diblock copolymers by ring-opening polymerization of LA. Nanoparticles prepared using amphiphilic block copolymers can form active drug delivery systems. Nanoparticles encapsulate Triptolide (HY-32735), which can avoid the disadvantage of Triptolide’s poor water solubility and reduce its toxicity.

HY-W1123936H

DBCO-PEG10000-FA

DBCO-PEG10000-Folate

Biochemical Assay Reagents

DBCO-PEG10000-FA (DBCO-PEG10000-Folate) is a multifunctional bioconjugation reagent, which is a copolymer of DBCO and Folic acid (FA) (HY-16637) and can target folate receptors (FR). Folate receptors are highly overexpressed on the surface of many cancer cells (such as lung cancer, nasopharyngeal cancer, ovarian cancer, etc.), but exhibit extremely low expression levels in normal tissues. DBCO-PEG-FA can be used for click chemistry conjugation via its DBCO terminal, and thus applies to various bioconjugation and drug delivery applications .

HY-W1123936E

DBCO-PEG5000-FA

DBCO-PEG5000-Folate

Biochemical Assay Reagents

DBCO-PEG5000-FA (DBCO-PEG5000-Folate) is a multifunctional bioconjugation reagent, which is a copolymer of DBCO and Folic acid (FA) (HY-16637) and can target folate receptors (FR). Folate receptors are highly overexpressed on the surface of many cancer cells (such as lung cancer, nasopharyngeal cancer, ovarian cancer, etc.), but exhibit extremely low expression levels in normal tissues. DBCO-PEG-FA can be used for click chemistry conjugation via its DBCO terminal, and thus applies to various bioconjugation and drug delivery applications .

HY-15947G

Ravoxertinib

GDC-0994

Biochemical Assay Reagents

Cat. No.	상품명	Target	Research Area

HY-13673A

Goserelin acetate 1 Publications Verification ICI-118630 acetate	GnRH Receptor Apoptosis	Endocrinology Cancer
Goserelin acetate (ICI-118630 acetate), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin acetate can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

HY-P5321

bFGF (119-126) 5 Publications Verification	FGFR	Cancer
bFGF (119-126) is a ligand of bFGF. The complex formed by bFGF (119-126) and bFGF can bind to FGFR1, while inhibiting the bFGF-FGFR1 interaction, FGFR1 phosphorylation and downstream signaling pathways. Therefore, bFGF (119-126) induces cell apoptosis and inhibits cell proliferation, migration, angiogenesis and metastasis. When conjugated with a carrier, bFGF (119-126) enhances cellular uptake via FGFR-mediated endocytosis and serves as an effective FGFR-targeted ligand. When used in combination with ultrasound and Doxorubicin (HY-15142A), bFGF (119-126) significantly enhances the inhibitory effect on tumors. bFGF (119-126) is applicable to research related to lung cancer, breast cancer, glioblastoma and ovarian cancer .

HY-P0205

Saralasin [Sar1,Ala8] Angiotensin II	Angiotensin Receptor	Cardiovascular Disease Inflammation/Immunology
Saralasin ([Sar1,Ala8] Angiotensin II) is an octapeptide analog of angiotensin II. Saralasin is a competitive angiotensin II receptor antagonist with a K_i value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension .

HY-P1103

CTCE-9908 1 Publications Verification	CXCR	Cancer
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P5098

E(c(RGDfK))2	Integrin	Neurological Disease Cancer
E (c (RGDfK)) 2 is a αvβ3 integrin ligand and tumor-targeting agent. E (c (RGDfK)) 2 binds to αvβ3 integrin, mediates receptor-mediated endocytosis of conjugated payloads, and inhibits integrin-dependent cell adhesion to fibrinogen. E (c (RGDfK)) 2 inhibits the proliferation of cancer cells and endothelial cells. E (c (RGDfK)) 2 preferentially accumulates in orthotopic mouse breast tumors and human ovarian cancer xenograft tumors. E (c (RGDfK)) 2 can be used in research related to glioblastoma, lung cancer, breast adenocarcinoma and ovarian cancer .

HY-P10762

Ricorfotide vedotin CBP-1008; LDC 10B	Peptide-Drug Conjugates (PDCs) Folate Receptor (FR) TRP Channel	Cancer
Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .

HY-P0205B

Saralasin TFA [Sar1,Ala8] Angiotensin II TFA	Angiotensin Receptor	Cardiovascular Disease Inflammation/Immunology
Saralasin ([Sar1,Ala8] Angiotensin II) TFA is an octapeptide analog of angiotensin II. Saralasin TFA is a competitive angiotensin II receptor antagonist with a K_i value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin TFA can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension .

HY-P0009

Cetrorelix 1 Publications Verification SB-75	GnRH Receptor	Endocrinology
Cetrorelix is a potent gonadotrophin-releasing hormone (GnRH) antagonist. Cetrorelix inhibits the endogenous luteinizing hormone surge during ovarian stimulation. Cetrorelix reduces cyclophosphamide induced ovarian follicular destruction in mice .

HY-13545

ABT-510 1 Publications Verification	Apoptosis	Inflammation/Immunology Cancer
ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-P1654

A20FMDV2	Integrin	Cancer
A20FMDV2 is a highly selective αvβ6 integrin inhibitor with human IC₅₀ values of 3 nM and binds with at least 1000-fold selectivity over other RGD-binding integrins. A20FMDV2 binds to the integrin’s RGD-binding site, induces rapid integrin internalization, and delays post-internalization integrin recycling to the cell surface. A20FMDV2 can be used for the research of pancreatic cancer, breast cancer, colorectal cancer, ovarian cancer, oral squamous cell carcinoma .

HY-P0051

Lecirelin 2 Publications Verification	GnRH Receptor	Endocrinology Cancer
Lecirelin, a synthetic gonadotropin-releasing hormone (GnRH) analogue, acts as a GnRH agonist. Lecirelin is widely used for the research of bovine ovarian follicular cysts .

HY-13545B

ABT-510 acetate 1 Publications Verification	Apoptosis	Inflammation/Immunology Cancer
ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-P4190

Fsh receptor-binding inhibitor fragment(bi-10)	GnRH Receptor	Endocrinology
FSH receptor-binding inhibitor fragment(bi-10) is a potent FSH antagonist. FSH receptor-binding inhibitor fragment(bi-10) blocks the binding of FSH to FSHR, and alteres FSH action at the receptor level. FSH receptor-binding inhibitor fragment(bi-10) results in the suppression of ovulation and causes follicular atresia of mice. FSH receptor-binding inhibitor fragment(bi-10) has the potential for utilizing to restrain the carcinogenesis of ovarian cancer by down-regulating overexpression of FSHR and ERβ in the ovaries .

HY-P11078A

LARLLT TFA	EGFR	Cancer
LARLLT TFA is an EGFR-binding peptide. LARLLT has the potential for research of EGFR overexpressing cancers, such as lung, ovarian and colorectal cancer .

HY-P11078

LARLLT	EGFR	Cancer
LARLLT (D4) is an EGFR-binding peptide. LARLLT has the potential for research of EGFR overexpressing cancers, such as lung, ovarian and colorectal cancer .

HY-13673

Goserelin ICI 118630	GnRH Receptor Apoptosis	Endocrinology Cancer
Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

HY-P5407

HD5	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection Cancer
HD5 is an innate immune effector peptide and SARS-CoV Inhibitor. HD5 binds to the ligand-binding domain of angiotensin-converting enzyme-2 (ACE2) via multiple hydrogen bonds to competitively block the receptor, shielding it from viral recognition. HD5 can be used for the research of COVID-19, HPV16 infection, epithelial ovarian cancer, small-cell lung cancer, and colon cancer .

HY-P4102

Cyclic PSAP peptide	Peptides	Cancer
Cyclic PSAP peptide is a cyclic pentapeptide (DWLPK). Cyclic PSAP peptide exhibits agent-like properties and could inhibit metastatic spread and restrain tumor development in general in vivo .

HY-P0121B

ReACp53 scrambled peptide TFA	MDM-2/p53	Cancer
ReACp53 scrambled peptide TFA is a negative control for ReACp53 (HY-P0121). ReACp53 scrambled peptide can be used in the study of ovarian cancer .

HY-P2496

Endothelin 1 (swine, human), Alexa Fluor 488-labeled	Endothelin Receptor Fluorescent Dye NF-κB COX Prostaglandin Receptor Apoptosis TNF Receptor Interleukin Related MMP	Cardiovascular Disease Inflammation/Immunology Cancer
Endothelin 1 (swine, human), Alexa Fluor 488-labeled is an Endothelin-1 conjugated with Alexa Fluor 488 (HY-D1304). Endothelin-1 is an endogenous vasoconstrictor and agonist of ETA/ETB receptor. Endothelin 1 (swine, human) exerts effects including promoting mitosis, angiogenesis, tumor invasion and metastasis, and inhibiting apoptosis. Endothelin 1 (swine, human) induces inflammation and oxidative stress by activating the NF-κB pathway. Endothelin 1 (swine, human), Alexa Fluor 488-labeled is specifically designed for fluorescence imaging, flow cytometry or receptor localization studies, and can be used in research related to sepsis, atherosclerosis, systemic inflammatory response syndrome, cancer and congestive heart failure .

HY-P4144

Onvitrelin ucalontide Phor18-LHRH (338613); EP-100	GnRH Receptor	Endocrinology Cancer
Onvitrelin ucalontide ([Phor18-LHRH (338613)]) is an analogue of luteinizing hormone releasing hormone (LHRH) with antineoplastic activity. Onvitrelin ucalontide is a peptide with sequences of KFAKFAKKFAKFAKKFAKQHWSYGLRPG. Onvitrelin ucalontide effectively inhibits breast cancer, ovarian cancer and prostate cancer xenografts in mouse model .

HY-P11219

TAT-PDHPS1	YAP	Cancer
TAT-PDHPS1 is a YAP inhibitor composed of the endogenous peptide PDHPS1 and the cell-penetrating peptide sequence TAT. PDHPS1 binds to protein phosphatase 2 phosphatase activator (PTPA), an essential activator of protein phosphatase 2A (PP2A), leading to increased YAP phosphorylation, which inactivates YAP and suppresses the expression of its downstream target genes. TAT-PDHPS1 is potentially useful in ovarian cancer research .

HY-P2228

Chlamydocin (purity≥70%)	HDAC Apoptosis	Cancer
Chlamydocin (purity≥70%), a fungal metabolite, is a highly potent HDAC inhibitor, with an IC₅₀ of 1.3 nM. Chlamydocin (purity≥70%) exhibits potent antiproliferative and anticancer activities. Chlamydocin (purity≥70%) induces apoptosis by activating caspase-3 .

HY-P0121A

ReACp53 scrambled peptide	MDM-2/p53	Cancer
ReACp53 scrambled peptide is a negative control for ReACp53 (HY-P0121). ReACp53 scrambled peptide can be used in the study of ovarian cancer .

HY-P11738

Murine ZP3 peptide (330-342)	Peptides	Endocrinology
Murine ZP3 peptide (330-342) is a zona pellucida 3 polypeptide fragment with the amino acid sequence NSSSSQFQIHGPR. Murine ZP3 peptide (330-342) induces autoimmune premature ovarian failure (POF). Murine ZP3 peptide (330-342) can be used for the research of premature ovarian failure .

HY-P1103A

CTCE-9908 TFA	CXCR	Cancer
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P11018

(123B9)2-L2-PTX	Peptide-Drug Conjugates (PDCs) Ephrin Receptor	Cancer
(123B9)2-L2-PTX is an EphA2-agonistic peptide-drug conjugate (PDC). (123B9)2-L2-PTX consists of a dimeric 123B9 (HY-P10579) and Paclitaxel (HY-B0015). (123B9)2-L2-PTX significantly reduces circulating tumor cells and inhibits lung tumor metastasis in breast-cancer-Metastasis mice model. (123B9)2-L2-PTX can be used for cancers research, such as melanomas and ovarian and breast cancers .

HY-P0205A

Saralasin acetate hydrate [Sar1,Ala8] Angiotensin II acetate hydrate	Angiotensin Receptor	Cardiovascular Disease Inflammation/Immunology
Saralasin ([Sar1,Ala8] Angiotensin II) acetate hydrate is an octapeptide analog of angiotensin II. Saralasin acetate hydrate is a competitive angiotensin II receptor antagonist with a K_i value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin acetate hydrate can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension .

HY-P11011

Peptide R54 Pep R54; CXCR4 antagonist peptide 19	CXCR	Cancer
Peptide R54 (Pep R54; CXCR4 antagonist peptide 19) is an antagonistic peptide targeting CXCR4 with significant anticancer activity. Peptide R54 inhibits CXCR4-dependent cell migration, epithelial-mesenchymal transition, and lung metastasis development, with better serum stability and higher CXCR4 affinity than the lead compound (IC₅₀=20 nM). Peptide R54 synergizes with anti-PD-1 therapy to exert anti-tumor activity in vivo, enhances granzyme activity, and reduces infiltration of Foxp3 cells. Peptide R54 can be used in the study of colon cancer, ovarian cancer, and melanoma .

HY-P10010

DB21, Galectin-1 Antagonist	Galectin	Cancer
DB21, Galectin-1 Antagonist is a dibenzofuran conjugated peptidomimetic that acts as an allosteric inhibitor of galectin-1 (GAL1)binding to cell surface glycans. DB21, Galectin-1 Antagonis increases inhibition of angiogenesis and tumour growth in melanoma, lung adenocarcinoma and ovarian cancer models .

HY-P0037

Org-30850 Org 30850ANT	GnRH Receptor	Endocrinology
Org-30850 is a potent LHRH antagonist designed for treating hormone-dependent disorders. In animal studies, a single subcutaneous dose effectively inhibited ovulation in rats and significantly reduced testosterone levels in male rats for up to 48 hours post-administration. Daily doses of Org-30850 in female rats suppressed estrous cycles, decreased uterine and ovarian weights, and lowered estradiol and FSH serum levels. In male rats, prolonged treatment resulted in reversible reductions in gonadal function and testosterone levels, with almost complete recovery observed after cessation of treatment. Unlike comparable LHRH antagonists, Org-30850 exhibited minimal injection site irritation and no edematous reactions, suggesting a more favorable therapeutic profile .

HY-P11678

HDAC-IN-100	HDAC Apoptosis Caspase	Cancer
HDAC-IN-100 is a histone deacetylase inhibitor with an IC₅₀ of 0.038 μM against HDAC1, 0.283 μM against HDAC2, and 0.586 μM against HDAC3. HDAC-IN-100 acts as a chemosensitizer and apoptosis inducer, activates caspase 3/7, and reverses Cisplatin (HY-17394) resistance. HDAC-IN-100 exerts antiproliferative effects in ovarian cancer cells and squamous cancer cells. HDAC-IN-100 is applicable for research related to ovarian cancer, squamous cell carcinoma, and Cisplatin (HY-17394)-resistant squamous cell carcinoma .

HY-P11011A

Peptide R54 acetate Pep R54 acetate; CXCR4 antagonist peptide 19 acetate	CXCR ERK Akt	Cancer
Peptide R54 acetate (Pep R54 acetate) is a CXCR4 antagonist. Peptide R54 acetate inhibits CXCL12-dependent activation of pERK1/2 and pAKT. The combination of Peptide R54 acetate and Nivolumab (HY-P9903) suppresses melanoma growth. Peptide R54 (acetate) is applicable to research related to melanoma and ovarian cancer .

HY-182259

Montanastatin	Peptides	Cancer
Montanastatin is an antitumor agent that can be isolated from the terrestrial actinomycete Streptomyces anulatus. Montanastatin inhibits the growth of various cancer cells. Montanastatin can be used in research related to lymphocytic leukemia, ovarian cancer, brain cancer, renal cancer, lung cancer, colon cancer and melanoma .

HY-P5407A

HD5 TFA	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection Cancer
HD5 TFA is an innate immune effector peptide and SARS-CoV Inhibitor. HD5 TFA binds to the ligand-binding domain of angiotensin-converting enzyme-2 (ACE2) via multiple hydrogen bonds to competitively block the receptor, shielding it from viral recognition. HD5 TFA can be used for the research of COVID-19, HPV16 infection, epithelial ovarian cancer, small-cell lung cancer, and colon cancer .

HY-P11716

HYD-1	ERK	Cancer
HYD-1 is a D-amino acid tumor cell adhesion peptide. HYD-1 contains overlapping linear peptide elements required for adhesion, migration blocking, and ERK signaling activation. HYD-1 supports adhesion of breast, prostate, ovarian, and pancreatic tumor cells, and shows no effect on tumor cell cycle distribution. HYD-1 can be used for the research of prostate cancer .

HY-P11662

NLS peptide	Peptides	Cancer
NLS peptide is a nuclear localization signal peptide, a short amino acid sequence that can be recognized by nuclear transport machinery (such as the Importin protein complex). NLS peptide can directionally transport the molecules or nanoparticles linked to it into the nucleus, and the N-terminal Cys terminus can be used for subsequent coupling. NLS peptide can be used to construct nucleus-specific imaging probes and nucleus-targeted nanoparticles

HY-P11280A

PRAME peptide (425-433) acetate	Melanocortin Receptor	Cancer
PRAME peptide (425-433) acetate is a proteasome-degraded peptide derived from the cancer-testis antigen PRAME (Preferentially Expressed Antigen in Melanoma). PRAME peptide (425-433) acetate is restricted by HLA-A02:01 and can serve as a target for bispecific T cell engager therapy in the context of major histocompatibility complex I presentation. PRAME peptide (425-433) acetate shows application potential in various malignant tumors and is widely suitable for research related to solid tumors, melanoma, ovarian* cancer, endometrial cancer, and lung cancer (including lung adenocarcinoma and lung squamous cell carcinoma). PRAME peptide (425-433) acetate can be used to explore disease of triple-negative breast cancer, diffuse large B-cell lymphoma, and head and neck squamous cell carcinoma .

HY-P11658

Anticancer peptoid 1 Peptoid 1	Peptides	Cancer
Anticancer peptoid 1 (Peptoid 1) is a peptoid with antitumor activity. Anticancer peptoid 1 exerts cytotoxicity primarily via plasma membrane damage. Anticancer peptoid 1 exerts cytotoxicity against a broad range of cancer cell lines, including those with multidrug resistance. Anticancer peptoid 1 inhibits tumor growth in a human breast cancer xenotransplantation mouse model without noticeable acute adverse effects. Anticancer peptoid 1 can be used for the research of cancer, such as breast cancer, and prostate cancer .

HY-P11599

NOTA-SP2A-FAPT	FAP	Cancer
NOTA-SP2A-FAPT is a fibroblast activation protein (FAP) ligand. NOTA-SP2A-FAPT can be adiolabeled and exhibits rapid renal excretion with fast kidney tissue clearance, accumulates rapidly in and retains high levels in FAP-positive tumor xenografts to enable clear tumor visualization. NOTA-SP2A-FAPT can be used as a tracer of cancer .

Cat. No.	상품명

HY-K6123

*Human Ovarian* Cancer Organoid Kit**
MCE Human Ovarian Cancer Organoid Kit includes a basic culture medium for ovarian cancer organoids, as well as culture supplements, and is designed for the effective construction of human ovarian cancer organoids.

HY-K6123A

*Human Ovarian* Cancer Organoid Complete Culture Medium**
MCE Human Ovarian Cancer Organoid Complete Culture Medium is a pre-mixed, ready-to-use formulation composed of a basal ovarian cancer organoid medium and multiple key culture supplements at optimized ratios. This medium requires no additional preparation and enables the efficient and stable establishment of human ovarian cancer organoid models.

Cat. No.	상품명	Target	Research Area	Image

HY-P99225

Mirvetuximab 2 Publications Verification M9346A	Antifolate ADC Antibody	Cancer
Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research .

HY-P99592

Solitomab AMG 110	CD3	Cancer
Solitomab (AMG 110) is a bispecific anti-CD3 and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer .

HY-P99386

Vesencumab MNRP-1685A	Complement System EGFR PDGFR p38 MAPK	Cancer
Vesencumab (MNRP-1685A) is IG1 antibody against neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer .

HY-P99396

Spesolimab BI 655130	Interleukin Related	Inflammation/Immunology
Spesolimab (BI 655130) is a mouse-derived humanized IgG1k antibody against IL-36R. IL-36 plays an important role in the immune system and Spesolimab is being investigated in palmoplantar pustulosis (PPP). Spesolimab was associated with a reduction in biomarkers associated with the innate, Th1/Th17 and neutrophil pathways .

HY-P991097

Pumitamig PM-8002; BNT-327	VEGFR PD-1/PD-L1	Cancer
Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy .

HY-P99101

Vobramitamab AEX-4089; MGC026 antibody	ADC Antibody	Cancer
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma .

HY-P99828

Cofetuzumab PF-06523435; hu24	ADC Antibody RET PERK ROR	Cancer
Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. The expression system of Cofetuzumab is typically CHO (Chinese hamster ovary) cells. Cofetuzumab downregulates PTK7 expression, modulates its downstream signaling pathways, and inhibits tumor sphere formation of ovarian cancer cells. Cofetuzumab can be used to synthesize the ADC molecule Cofetuzumab pelidotin (HY-P99829). Cofetuzumab is applicable to the research of tumors such as ovarian cancer .

HY-P99547

Trastuzumab duocarmazine (vic)-Trastuzumab duocarmazine	Antibody-Drug Conjugates (ADCs)	Cancer
Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas .

HY-P99225A

Mirvetuximab (powder) 2 Publications Verification M9346A (powder)	Antifolate ADC Antibody	Cancer
Mirvetuximab (M9346A) (powder) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab (powder) is the antibody moiety of folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research .

HY-P990717

Brenetafusp IMC-F106C	CD3	Cancer
Brenetafusp is a TCR/anti-CD3 bispecific fusion protein, consisting of a TCR targeting the PRAME peptide and an anti-CD3 scFv effector domain. Brenetafusp redirects CD3 ⁺ T cells to kill PRAME ⁺ tumor cells. Brenetafusp can be used in research related to cutaneous melanoma, non-small cell lung cancer, ovarian cancer, endometrial cancer, triple-negative breast cancer, and small cell lung cancer .

HY-P99268

Seribantumab SAR 256212; MM 121; Anti-Human ERBB3/ErbB 3 Recombinant Antibody	EGFR Apoptosis	Cancer
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .

HY-P99262

Imalumab BAX69; Anti-Human MIF Recombinant Antibody	Macrophage migration inhibitory factor (MIF)	Cancer
Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer .

HY-P991577

DS-8895 DS-8895A	Ephrin Receptor	Cancer
DS-8895(DS-8895A) is an anti-EphA2 monoclonal antibody with specific binding to EphA2 receptors and EphA2-expressing cells. DS-8895, when conjugated with ⁸⁹Zr, ¹¹¹In, or ¹²⁵I, supports molecular imaging of EphA2 expression in xenograft models. DS-8895 allows noninvasive measurement of EphA2 expresssion in tumors in vivo. .

HY-P99229

Upifitamab 2 Publications Verification XMT-1535; Upinitatug	ADC Antibody	Cancer
Upifitamab is a humanized monoclonal antibody targeting NaPi2b. Upifitamab can be used to synthesize ADC such as Upfitamab rilsodotin. Upfitamab rilsodotin can be used in research for solid tumors including high-grade serious epithelial ovarian, fallopian tube and primary peritoneal cancer (OC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99276

Abagovomab 1 Publications Verification Anti-Human CA-125 Recombinant Antibody	Inhibitory Antibodies	Cancer
Abagovomab (Anti-Human CA-125 Recombinant Antibody) is a mouse monoclonal anti-idiotypic antibody that targets the tumor-associated antigen CA-125. Produced by mouse hybridoma cells, Abagovomab mimics the human TAA, CA-125. Abagovomab also induces humoral and cellular immune responses against ovarian cancer (OC) .

HY-P99667

Ipafricept 4 Publications Verification OMP-54F28; FZD8-Fc	Wnt	Cancer
Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .

HY-P991372

Anti-TROP2 Antibody RN927C antibody	TROP2	Cancer
Anti-TROP2 Antibody (RN927C antibody) is a human monoclonal antibody targeting Trop-2. Anti-TROP2 Antibody exerts in vitro inhibitory effects on a variety of tumor cell lines. Anti-TROP2 Antibody exhibits anti-tumor activity in mouse pancreatic PDX, ovarian PDX, lung PDX and triple-negative breast cancer (TNB) PDX models. Anti-TROP2 Antibody can be used for research on pancreatic cancer, ovarian cancer, lung cancer and triple-negative breast cancer .

HY-P99377

Navicixizumab OMP-305B83; Anti-DLL4 Reference Antibody (navicixizumab)	Notch	Cancer
Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer .

HY-P99672

Istiratumab MM 141; MM-005	IGF-1R EGFR	Cancer
Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers .

HY-P99291

Etaracizumab LM609; MEDI-522	Integrin Apoptosis Akt	Cancer
Etaracizumab (LM 609) is an α_vβ₃ integrin IgG mAb. Etaracizumab is developed to target α_vβ₃+ cancer cells via NK cell-mediated cytotoxicity. Etaracizumab sterically hinders access of large ligands to the RGD-binding pocket, without obstructing it. Etaracizumab decreases p-Akt in vitro. Etaracizumab can decrease cancer proliferation and invasion. Etaracizumab induces tumor cell apoptosis, and inhibition ofα_vβ₃-mediated cell adhesion, endothelial cell migration and osteoclast-mediated bone resorption. Etaracizumab can be studied in anti-tumor research against cancers such as ovarian cancer, metastatic melanoma as well as advanced solid tumors. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99605

Cinrebafusp alfa PRS 343	EGFR TNF Receptor	Cancer
Cinrebafusp alfa (PRS 343) is a high affinity CD137/HER2 bispecfic anticalin-based drug. Cinrebafusp alfa binds to recombinant human HER2 (K_d=0.3 nM) and human monomeric CD137 (4-1BB; K_d=5 nM). Cinrebafusp alfa facilitates T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering and activation, further enhancing T-cell receptor-mediated activity and leading to tumor destruction. Cinrebafusp alfa has the potential for HER2+ solid tumors research .

HY-P991526

M701	CD3	Cancer
M701 is a T-cell engager bispecific humanized antibody targeting epithelial cell adhesion molecule (EpCAM) and cluster of differentiation 3 (CD3). M701 binds to EpCAM on tumor cells and CD3 on T cells, thereby linking the two cell populations to achieve targeted cytotoxicity and T cell-mediated cytotoxicity. M701 is applicable to research related to advanced epithelial solid tumors .

HY-P99463

Batiraxcept 2 Publications Verification AVB-500; AVB-S6-500	TAM Receptor PI3K Akt p38 MAPK	Cancer
Batiraxcept (AVB-500; AVB-S6-500) is a selective, soluble AXL receptor and GAS6 inhibitor that targets the GAS6-AXL signaling axis. Batiraxcept is orally inactive and does not cross the blood-brain barrier. Batiraxcept competitively binds to GAS6 ((K_D <1 nM), preventing its interaction with the AXL receptor tyrosine kinase, thereby inhibiting downstream PI3K/AKT and MAPK signaling pathways, reducing tumor cell glycolysis, angiogenesis, and metastatic potential. Batiraxcept has demonstrated antitumor activity in preclinical models of endometrial, cholangiocarcinoma, and ovarian cancer by inhibiting tumor growth, invasion, and metastasis .

HY-P99413

IMAB027 ASP1650	HCV	Cancer
IMAB027 (ASP1650) is a specific anti-CLDN6 mAb, while CLDN6 (Claudin 6) is a tight junction membrane protein, aberrantly expressed in various human cancer types, ovarian cancers particularly. IMAB 027 shows anti-tumor activity, and induces apoptosis in CLDN6 ⁺ ovarian and testicular cancer cell lines .

HY-P991723

Varsetatug CX-2051 antibody	ADC Antibody Transmembrane Glycoprotein	Cancer
Varsetatug (CX-2051 antibody) is a humanized IgG1κ monoclonal antibody inhibitor targeting EpCAM/TROP1/CD326. Varsetatug serves as the antibody component of the ADC compound CX-2051. It can be used in research on cancers including breast cancer, prostate cancer and ovarian cancer .

HY-P99593

Sofituzumab vedotin DMUC5754A	Antibody-Drug Conjugates (ADCs)	Cancer
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer .

HY-P99785

Opucolimab HLX20; HLX43 antibody	PD-1/PD-L1 ADC Antibody	Cancer
Opucolimab (HLX20) is an engineered anti-PD-L1 humanised IgG1 antibody. Opucolimab, when conjugated with camptothecin toxoid, yields the PD-L1-targeting ADC, HLX43 (HY-177439). HLX43 can be used for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), melanoma (MEL), ovarian cancer (Ovc) research .

HY-P99970

Lifastuzumab	ADC Antibody Sodium Phosphate Cotransporter	Cancer
Lifastuzumab is a humanized anti-NaPi2b IgG1 monoclonal antibody. Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) (HY-15162) through ADC Linker to form an antibody-drug conjugate (ADC) Lifastuzumab vedotin (HY-P99705) with anticancer activity. Lifastuzumab vedotin can be studied in research for non-small cell lung cancer and ovarian cancer. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99925

Enoticumab REGN421	Notch	Metabolic Disease Cancer
Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively .

HY-P991196

Anti-CD24 Antibody (SWA11)	Transmembrane Glycoprotein	Cancer
Anti-CD24 Antibody (SWA11) is a human IgG1 monoclonal antibody (mAb) targeting CD24, with high affinity and specificity for tumor cells expressing CD24. Anti-CD24 Antibody (SWA11) binds to CD24 on tumor cells, triggers endocytosis, alters STAT3-dependent gene expression, regulates Src phosphorylation, and blocks CD24-mediated signaling pathways. Anti-CD24 Antibody (SWA11) exhibits anticancer effects, such as against lung cancer and ovarian cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990831

Anti-MUC1/CD227 Antibody (C595 (NCRC48))	Mucin	Cancer
Anti-MUC1/CD227 Antibody (C595 (NCRC48)) is a kind of mouse IgG3 κ chimeric antibody inhibitor, targeting to human MUC1/CD227. Anti-MUC1/CD227 Antibody (C595 (NCRC48)) specifically recognizes and binds to the MUC1 protein, which is overexpressed and abnormally glycosylated on the surface of tumor cells, thereby precisely killing cancer cells. Anti-MUC1/CD227 Antibody (C595 (NCRC48)) can be used for the researches of cancer, such as ovarian cancer .

HY-P99506

Tamrintamab SC-003 mAb; SC-Mab003; SC34.28ss1	ADC Antibody	Cancer
Tamrintamab (SC-003 mAb, SC-Mab003, SC34.28ss1) is an ADC Antibody targeting to dipeptidase 3 (DPEP3 or MBD3). DPEP3 is a glycosyl phosphatidylinositol anchored metallopeptidase that is overexpressed in ovarian tumors. Tamrintamab can specifically bind DPEP3-expressing cells to produce cytotoxicity. Tamrintamab can be used in ovarian cancer research .

HY-P990953

Zubotamig Gen1047	CD3	Cancer
Zubotamig (Gen1047) is an CD3E/VTCN1-targeting Ig(G1 -κ_G1 -λ2) type chimeric human antibody. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). Zubotamig induces T-cell mediated cytotoxicity of B7H4-positive tumor cells, triggers T-cell activation, and induces cytokine release from T cells in the presence of B7H4-expressing tumor cells. Zubotamig demonstrates antitumor activity in mouse patient-derived xenograft (PDX) models. Zubotamig can be used for the research of solid cancers (including breast, ovarian and lung cancer) .

HY-P99179

CTX-2026	Inhibitory Antibodies	Cancer
CTX-2026 is a fully human antibody that binds to CD277. CTX-2026 shows an anti-tumor effect on ovarian tumor models. CTX-2026 can be used for the research of cancer .

HY-P99121

Anti-Mouse/Human CD11b Antibody (M1/70)	Integrin	Inflammation/Immunology Cancer
Anti-Mouse/Human CD11b Antibody (M1/70) is an anti-mouse CD11b IgG2b monoclonal antibody. Anti-Mouse/Human CD11b Antibody (M1/70) can significantly inhibit the adhesion between dendritic cells (DCs) and platelets. Anti-Mouse/Human CD11b Antibody (M1/70) can kill ovarian cancer cells and inhibit their migration. Anti-Mouse/Human CD11b Antibody (M1/70) can alleviate renal fibrosis and inflammation. Anti-Mouse/Human CD11b Antibody (M1/70) can be used for researches on inflammation conditions and cancer such as ischemia-reperfusion injury (IRI), thrombotic inflammatory conditions and ovarian cancer .

HY-P991292

AB-3A4	ADC Antibody	Cancer
AB-3A4 is a human IgG1 monoclonal antibody (mAb) targeting KAAG1. AB-3A4 can be used in the study of ovarian cancer, triple-negative breast cancer, and prostate cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P990251

Anti-Human/Mouse denatured collagen type-I Antibody (XL313)	MMP Collagen PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Human/Mouse denatured collagen type-I Antibody (XL313) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to human/mouse denatured collagen type-I. Anti-Human/Mouse denatured collagen type-I Antibody (XL313) selectively binds to proteolyzed collagen type I. Anti-Human/Mouse denatured collagen type-I Antibody (XL313) reduces PD L1 levels in tumor cells. Anti-Human/Mouse denatured collagen type-I Antibody (XL313) can be used for the researches of cancer and inflammation, such as such as ovarian tumor .

HY-P99881

Rolinsatamab talirine ABBV 176	Antibody-Drug Conjugates (ADCs)	Cancer
Rolinsatamab talirine (ABBV 176) is a prolactin receptor (PRLR)-targeting antibody-drug conjugate (ADC), compoused of Rolinsatamab (HY-P99238) and SGD-1882 (HY-101127). Rolinsatamab talirine binds to PRLR to deliver a cytotoxin to tumor cells. Rolinsatamab talirine induces DNA damage, and exhibits cytotoxicity against multiple breast tumor models, including triple negative and low PRLR-expressing models. Rolinsatamab talirine demonstrates enhanced anti-tumor activity in several breast cancer models. Rolinsatamab talirine can be used for the research of breast cancer, hepatocellular carcinoma, ovarian cancer, endometrial cancer, prostate cancer, colorectal cancer, adrenocortical carcinoma, and solid tumors .

HY-P9943

Igovomab	Transmembrane Glycoprotein	Cancer
Igovomab is a monoclonal antibody for imaging. Igovomab can be used for ovarian cancer research .

HY-P991417

LYN00101	VEGFR	Cancer
LYN00101 is a human monoclonal antibody (mAb) targeting VEGFA. LYN00101 can be used in Cervical cancer, Colorectal cancer, Gastric cancer and Ovarian cancer research .

HY-P991315

Anti-MSLN/Mesothelin (h7D9.v3) RG7600 antibody		Cancer
Anti-MSLN/Mesothelin (h7D9.v3) is a human monoclonal antibody (mAb) targeting MSLN. Anti-MSLN/Mesothelin (h7D9.v3) can be used in ovarian cancer, mesothelioma, and pancreatic cancer research .

HY-P991689

Girancitug	VEGFR	Cancer
Girancitug is a humanized IgG1κ monoclonal antibody inhibitor targeting VEGFR2/KDR/CD309. Girancitug effectively inhibits angiogenesis. Girancitug can be used for anti-angiogenic therapy in cancers like colorectal and ovarian cancer research .

HY-P990830

Anti-MUC16 Antibody (VK8)	Mucin	Cancer
Anti-MUC16 Antibody (VK8) is a kind of mouse IgG1 κ chimeric antibody inhibitor, targeting to human MUC16. Anti-MUC16 Antibody (VK8) reacts with human MUC16 also known as carbohydrate antigen 125 (CA125). Anti-MUC16 Antibody (VK8) Anti-MUC16 Antibody (VK8) can be used for detection of tumor marker, such as ovarian cancer .

HY-P991608

CTM01 7F11C7	Mucin	Cancer
CTM01 is a murine IgG1 (or humanized IgG4) monoclonal antibody inhibitor targeting MUC1. CTM01 has a broad spectrum anticancer activity against solid tumors of epithelial origin, such as breast, lung and ovarian cancer .

HY-P990873

Anti-BRCA1 Antibody (BR64)	DNA/RNA Synthesis	Cancer
Anti-BRCA1 Antibody (BR64) is a kind of mouse IgG1 κ chimeric antibody, targeting to human BRCA1. Anti-BRCA1 Antibody (BR64) reacts with BRCA1 (Breast cancer susceptibility gene 1) involved in tumor suppression, transcription, genomic stability, DNA repair and recombination. Anti-BRCA1 Antibody (BR64) can be used for the detections of immunofluorescence, western blot, and immunoprecipitation in cancer, such as breast and ovarian cancer .

HY-P991310

Lpathomab LT3015; LT-3000	LPL Receptor	Neurological Disease Cancer
Lpathomab (LT3015; LT-3000) is a human IgG1 monoclonal antibody (mAb) targeting LPA. Lpathomab reduces the release of IL-8 and IL-6 cytokines in SKOV3 cells and blocks LPA-triggered tumor cell migration. Lpathomab reduces neovascularization in Matrigel plug and CNV models. Lpathomab inhibits brain injury in the CCI mouse model. Lpathomab can be used in the study of brain injury, ovarian cancer, diabetic neuropathy, and spinal cord injury. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P992004

KHK2805 RA15-7, HuRA15-7Acc	Folate Receptor (FR)	Cancer
KHK2805 (RA15-7) is a humanized antibody against folate receptor α (FOLR1), with a K_d of 0.647 nM for human FOLR1. KHK2805 binds to a unique epitope of FOLR1 and mediates antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity against FOLR1-expressing cells. KHK2805 exhibits cytotoxicity against both ovarian cancer cells and Platinum (HY-W096169D)-resistant ovarian cancer cells. KHK2805 can be used for the research of tumors such as ovarian cancer .

HY-P992441

PHST001	Transmembrane Glycoprotein	Cancer
PHST001 is a humanized anti-CD24 antibody. PHST001 binds cell-surface CD24, blocks CD24-Siglec10 interaction, and engages Fc receptors to promote macrophage-mediated tumor cell phagocytosis. PHST001 inhibits growth of breast cancer and ovarian cancer, and reduces metastatic lesions in mouse xenograft models. PHST001 can be used for the research of triple negative breast cancer, HER2+ breast cancer, metastatic tumors, and ovarian cancer .

HY-P992151

Sphingomab LT1002	LPL Receptor Interleukin Related	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Sphingomab (LT1002) is a mouse-derived IgG1 κ monoclonal antibody and also an inhibitor targeting S1P, with high affinity for S1P and a K_d value of 0.03 ± 0.002 nM. Sphingomab blocks S1P-mediated IL-8 release in ovarian cancer cells. Sphingomab exhibits anti-angiogenic activity in a mouse model of choroidal neovascularization. Sphingomab reduces peripheral blood lymphocyte counts. Sphingomab can be used in the research of ovarian cancer and age-related macular degeneration .

HY-P992003

IKS012 Antibody IKS01 Antibody	ADC Antibody	Cancer
IKS012 (IKS01) Antibody is a monoclonal antibody inhibitor targeting folate receptor α (FRA). IKS012 Antibody can be used to synthesize the antibody-drug conjugate (ADC) IKS012. IKS012 Antibody can be used to research related to platinum-resistant ovarian cancer .

Species:	Human (7) Mouse (2)
Tag:	His (6) Avi (1) Fc (3) Flag (1)
Source:	HEK293 (7) E. coli (2)

Cat. No.	Compare	상품명	Species	Source	Image

HY-P702884

	OTUD6B Protein, Human (Active, His, FLAG) DUB; OTUD6B; ovarian tumor domain	Human	E. coli
	OTUD6B Protein, Human (Active, His, FLAG) is the recombinant human-derived OTUD6B, expressed by E. coli , with N-His, Flag labeled tag. ,

HY-P72347

	CA125 Protein, Human (Biotinylated, HEK293, Fc-Avi) CA125 ovarian cancer antigen; CA-125; FLJ14303; MUC16	Human	HEK293
	The CA125 protein acts by binding to MSLN and plays a crucial role in forming a protective and lubricating barrier on mucosal surfaces. This interaction promotes heterotypic cell adhesion and is suggested to play an important role in peritoneal metastasis of ovarian cancer. CA125 Protein, Human (Biotinylated, HEK293, Fc-Avi) is the recombinant human-derived CA125 protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag.

HY-P7696

	CA125 Protein, Human (HEK293, His) 3 Publications Verification rHuCA125, His; CA125 ovarian cancer antigen; CA125; CA125MUC-16;	Human	HEK293
	CA125 is a giant mucin-like glycoprotein expressed by epithelial ovarian neoplasms and cells, which is an antigenic tumor marker. CA125 provides a protective, lubricating barrier against particles and infectious agents at mucosal surfaces. CA125 binds to mesothelin (MSLN) mediates heterotypic cell adhesion, contributing to the metastasis of ovarian cancer to the peritoneum by initiating cell attachment to the mesothelial epithelium. CA125 is widely used for monitoring with ovarian epithelial cancer. CA125 Protein, Human (HEK293, His) is a recombinant human cancer antigen 125 (CA125) with a His label and is expressed in HEK293 cells.

HY-P705458

	CA125 Protein, Human (642a.a, HEK293, His) rHuCA125, His; CA125 ovarian cancer antigen; CA125; CA125MUC-16	Human	HEK293

HY-P70296

	FOLR1 Protein, Human (HEK293, His) rHuFolate receptor alpha/FOLR1, His; Folate receptor alpha; FR-alpha; Adult folate-binding protein; FBP; Folate receptor 1; Folate receptor; ovarian tumor-associated antigen MOv18; FOLR1	Human	HEK293
	The FOLR1 protein is an important mediator of folate uptake, binding to folate and promoting the delivery of 5-methyltetrahydrofolate into cells. Studies show high affinity at neutral pH. FOLR1 Protein, Human (HEK293, His) is the recombinant human-derived FOLR1 protein, expressed by HEK293 , with C-His labeled tag.

HY-P704292

	FOLR1 Protein, Human (HEK293, Fc) rHuFolate receptor alpha/FOLR1, His; Folate receptor alpha; FR-alpha; Adult folate-binding protein; FBP; Folate receptor 1; Folate receptor; ovarian tumor-associated antigen MOv18; FOLR1	Human	HEK293
	The FOLR1 protein is an important mediator of folate uptake, binding to folate and promoting the delivery of 5-methyltetrahydrofolate into cells. Studies show high affinity at neutral pH. FOLR1 Protein, Human (HEK293, Fc) is the recombinant human-derived FOLR1 protein, expressed by HEK293, with C-hFc labeled tag.

HY-P72198

	FSHR Protein, Human (His) Follicle stimulating hormone receptor; Follicle stimulating hormone receptor isoform 1; Follicle-stimulating hormone receptor; Follitropin receptor; FSH receptor; FSH-R; Fshr; FSHR_HUMAN; FSHRO; LGR1; MGC141667; MGC141668; ODG1; ovarian dysgenesis 1	Human	E. coli
	FSHR, a G protein-coupled receptor, specifically recognizes follitropin (FSH) and activates PI3K-AKT and ERK1/ERK2 pathways by promoting cAMP production. Operating as a homotrimer, FSHR binds the heterodimeric FSH hormone, forming a functional unit for signal transduction. Its regulatory mechanisms involve interaction with ARRB2, and independently of FSH stimulation, it engages with APPL2, demonstrating versatility in diverse cellular contexts. FSHR Protein, Human (His) is the recombinant human-derived FSHR protein, expressed by E. coli , with N-6*His labeled tag.

HY-P70344

	FOLR1 Protein, Mouse (HEK293, His) rMuFolate receptor alpha/FOLR1, His; Adult folate-binding protein; FBP; folate binding protein; folate receptor 1 (adult); Folate receptor 1; folate receptor alpha; Folate receptor, adult; Folbp1; FOLR; FOLR1; FR-alpha; KB cells FBP; MOv18; ovarian tumor-associated antigen MOv18	Mouse	HEK293
	FOLR1 Protein, binding to folate and reduced folic acid derivatives, facilitates their delivery into cells. It maintains high affinity under neutral pH but undergoes a conformational change upon endocytosis, reducing affinity and releasing folates in slightly acidic pH. Crucial for embryonic development, cell proliferation, and renal folate reabsorption. FOLR1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived FOLR1 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P704619

	FOLR1 Protein, Mouse (HEK293, Fc) rMuFolate receptor alpha/FOLR1, His; Adult folate-binding protein; FBP; folate binding protein; folate receptor 1 (adult); Folate receptor 1; folate receptor alpha; Folate receptor, adult; Folbp1; FOLR; FOLR1; FR-alpha; KB cells FBP; MOv18; ovarian tumor-associated antigen MOv18	Mouse	HEK293
	FOLR1 Protein, binding to folate and reduced folic acid derivatives, facilitates their delivery into cells. It maintains high affinity under neutral pH but undergoes a conformational change upon endocytosis, reducing affinity and releasing folates in slightly acidic pH. Crucial for embryonic development, cell proliferation, and renal folate reabsorption. FOLR1 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived FOLR1 protein, expressed by HEK293, with C-hFc labeled tag.

Compare Products


Products	해외재고보유 - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / 해외재고보유 - + 장바구니에 담기 견적 받기

Host:	Mouse (2) Rabbit (5)
Reactivity:	Human (7)
Application:	IHC-P (6) ICC/IF (3) mIHC (1) IF-Tissue (3) IHC-F (2) WB (5) FC (4)
Isotype:	IgG (7)
Conjugation:	Non-conjugated (7) Biotin (1)
Clonality:	Monoclonal (5) Recombinant (4)
Modification:	Unmodified (5)

Cat. No.	Compare	상품명	Application	Reactivity	Image

HY-P81044

	MUC16 Antibody (YA890) MUC16; CA125; Mucin-16; MUC-16; ovarian cancer-related tumor marker CA125; CA-125; ovarian carcinoma antigen CA125	WB, ICC/IF, IHC-P, FC	Human
	MUC16 Antibody (YA890) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MUC16.

HY-P86753

	MUC16 Antibody (YA6445) CA 125; CA-125; CA125 ovarian cancer antigen; Cancer antigen 125; FLJ14303; MUC16_HUMAN; MUC 16; Mucin 16; MUC-16; Mucin 16 cell surface associated; Mucin16; ovarian cancer related tumor marker CA125; ovarian carcinoma antigen CA125; ovarian cancer-related tumor marker CA125	WB, ICC/IF, FC, IHC-P, IHC-F, IF-Tissue	Human
	MUC16 Antibody (YA6445) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to MUC16.

HY-P86753A

	MUC16 Antibody (YA6445)(PBS only) CA 125; CA-125; CA125 ovarian cancer antigen; Cancer antigen 125; FLJ14303; MUC16_HUMAN; MUC 16; Mucin 16; MUC-16; Mucin 16 cell surface associated; Mucin16; ovarian cancer related tumor marker CA125; ovarian carcinoma antigen CA125; ovarian cancer-related tumor marker CA125	WB, ICC/IF, FC, IHC-P, IHC-F, IF-Tissue	Human
	MUC16 Antibody (YA6445) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to MUC16.

HY-P81354

	FOLR1 Antibody (YA1099) FOLR1; FOLR; Folate receptor alpha; FR-alpha; Adult folate-binding protein; FBP; Folate receptor 1; Folate receptor; adult; KB cells FBP; ovarian tumor-associated antigen MOv18	IHC-P, mIHC	Human
	FOLR1 Antibody (YA1099) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Folate Binding Protein.

HY-P810310

	FOLR1 Antibody (YA9643) FOLR1; FOLR; Folate receptor alpha; FR-alpha; Adult folate-binding protein; FBP; Folate receptor 1; Folate receptor; adult; KB cells FBP; ovarian tumor-associated antigen MOv18	WB, IHC-P, IF-Tissue	Human
	FOLR1 Antibody (YA9643) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Folate Binding Protein.

HY-P81354A

	FOLR1 Antibody (YA1099)(PBS only) FOLR1; FOLR; Folate receptor alpha; FR-alpha; Adult folate-binding protein; FBP; Folate receptor 1; Folate receptor; adult; KB cells FBP; ovarian tumor-associated antigen MOv18	IHC-P	Human
	FOLR1 Antibody (YA1099) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Folate Binding Protein.

HY-P86790

	BRCA2 Antibody (YA6483) BRCA 2 antibody; BRCA1/BRCA2 containing complex subunit 2 antibody; Brca2 antibody; BRCA2, DNA repair associated antibody; BRCA2_HUMAN antibody; BRCC 2 antibody; BRCC2 antibody; Breast and ovarian cancer susceptibility gene early onset antibody; breast and ovarian cancer susceptibility protein 2 antibody; Breast cancer 2 early onset antibody; BRCA 2 antibody; BRCA1/BRCA2 containing complex subunit 2 antibody; Brca2 antibody; BRCA2, DNA repair associated antibody; BRCA2_HUMAN antibody; BRCC 2 antibody; BRCC2 antibody; Breast and ovarian cancer susceptibility gene early onset antibody; breast and ovarian cancer susceptibility protein 2 antibody; Breast cancer 2 early onset antibody; Breast Cancer 2 tumor suppressor antibody; Breast cancer susceptibility protein BRCA2 antibody; Breast cancer type 2 susceptibility protein antibody; BROVCA2 antibody; FACD antibody; FAD 1 antibody; FAD antibody; FAD1 antibody; FANCB antibody; FANCD 1 antibody; FANCD antibody; FANCD1 antibody; FANCD1 gene antibody; Fanconi anemia complementation group D1 antibody; Fanconi anemia group D1 protein antibody; GLM3 antibody; mutant BRCA2 antibody; OTTHUMP00000018803 antibody; OTTHUMP00000042401 antibody; PNCA2 antibody; XRCC11 antibody;	WB, FC	Human
	BRCA2 Antibody (YA6483) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to BRCA2.

Compare Products


Products	해외재고보유 - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / 해외재고보유 - + 장바구니에 담기 견적 받기

Cat. No.	상품명		Classification

HY-100433

PACMA 31 5 Publications Verification		Alkynes
PACMA 31 is an irreversible, orally active protein disulfide isomerase (PDI) inhibitor with an IC₅₀ of 10 μM. PACMA 31 forms a covalent bond with the active site cysteines of PDI. PACMA 31 shows tumor targeting ability and significantly suppresses ovarian tumor growth without causing toxicity to normal tissues . PACMA 31 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-B1012

Quinestrol W-3566		Alkynes
Quinestrol (W-3566) is an orally effective synthetic estrogen compound that acts on CYP3A4, CYP1A2, and GnRH. Quinestrol interferes with GnRH release and disrupts the hypothalamic-pituitary-ovarian axis. Quinestrol downregulates the gene expression of follicle-stimulating hormone β and luteinizing hormone β, induces oxidative stress, damages reproductive organs, reduces sperm density and motility, increases sperm malformation rate, and alters the levels of sex hormones such as testosterone, luteinizing hormone, estradiol, and progesterone. Quinestrol can be used in studies related to reproductive function regulation .

HY-W1123936B

DBCO-PEG1000-FA DBCO-PEG1000-Folate		DBCO
DBCO-PEG1000-FA (DBCO-PEG1000-Folate) is a multifunctional bioconjugation reagent, which is a copolymer of DBCO and Folic acid (FA) (HY-16637) and can target folate receptors (FR). Folate receptors are highly overexpressed on the surface of many cancer cells (such as lung cancer, nasopharyngeal cancer, ovarian cancer, etc.), but exhibit extremely low expression levels in normal tissues. DBCO-PEG-FA can be used for click chemistry conjugation via its DBCO terminal, and thus applies to various bioconjugation and drug delivery applications .

HY-147526

RM-581		Alkynes
RM-581, aminosteroid, is an orally active anticancer agent. RM-581 shows anticancer potency against pancreatic, breast, prostate, and ovarian cancers. RM-581 induces endoplasmic reticulum stress and apoptosis via disturbance of cancer cell cholesterol homeostasis. RM-581 can be used for the research of cancer, such as prostate cancer and breast cancer .

HY-10822

Idetrexed BGC 945; ONX-0801; CB 300945		Alkynes
Idetrexed (ONX 0801) is a thymidylate synthase (TS) inhibitor with a K_i of 1.2 nM. Idetrexed can be specifically transported into α-folate receptor (α-FR)-overexpressing tumors, such as ovarian cancer .

HY-134061

Arecaidine propargyl ester hydrobromide		Alkynes
Arecaidine propargyl ester hydrobromide is an agonist of M2 muscarinic acetylcholine receptors and has the activity of inhibiting tumor cell proliferation. The application of arecaidine propargyl ester hydrobromide has shown that it can reduce the number of ovarian cancer cells in vitro and induce apoptosis and the production of reactive oxygen species (ROS) at specific concentrations. Arecaidine propargyl ester hydrobromide can also arrest cells at the G2/M phase of the cell cycle and increase the percentage of abnormal mitosis. Arecaidine propargyl ester hydrobromide is more sensitizing to ovarian surface epithelial cells with higher M2 receptor levels than to cancer cells. Arecaidine propargyl ester hydrobromide exhibits the effect of lowering arterial blood pressure when interacting with the cardiovascular system in a natural physiological state, indicating its potential pharmacological application .

HY-B1341

Norethynodrel Enidrel; SC-4642; NSC 15432		Alkynes
Norethynodrel (Enidrel; SC-4642) is an orally active progestogen analog that reduces estrogen-like effects and enhances progestogen-like responses in endometrial stromal cells. Norethynodrel also promotes cell maturation and predecidual cell formation by inducing organelle hyperplasia and glycogen accumulation. Norethynodrel competitively inhibits drug-metabolizing enzymes in rat liver microsomes, thereby prolonging Pentobarbital sleep time, while exhibiting multiple effects including reduced body weight gain, attenuated heart rate elevation and ovulation inhibition. In mouse models, Norethynodrel significantly increases the incidence of mammary adenocarcinoma, cervical cancer and pituitary tumors. Norethynodrel can be used for mechanism research on related diseases such as mammary adenocarcinoma, cervical cancer, ovarian tubular adenoma and pituitary adenoma .

HY-160258

GDP-Fucose-Tz GDP-Fucose-Am-Tz		Tetrazine
GDP-Fucose-Tz (GDP-Fucose-Am-Tz) is a non-natural GDP-fucose analog bearing a Tetrazine group. As a precursor, GDP-Fucose-Tz enables the synthesis of GDP-fucose-ssDNA probes via inverse electron demand Diels-Alder reaction. GDP-Fucose-Tz participates in chemoenzymatic reactions to prepare GDP-fucose-Herceptin derivatives through conjugation with TCO-Herceptin .

HY-14375

CB 300919		Alkynes
CB 300919 is a quinazoline-based antitumour agent with high activity in the CH1 human ovarian tumour xenograft. CB 300919 has a continuous exposure (96 h) growth inhibition IC₅₀ value of 2 nM in human CH1 ovarian tumor xenograft . CB 300919 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-W1123936C

DBCO-PEG2000-FA DBCO-PEG2000-Folate		DBCO
DBCO-PEG2000-FA (DBCO-PEG2000-Folate) is a multifunctional bioconjugation reagent, which is a copolymer of DBCO and Folic acid (FA) (HY-16637) and can target folate receptors (FR). Folate receptors are highly overexpressed on the surface of many cancer cells (such as lung cancer, nasopharyngeal cancer, ovarian cancer, etc.), but exhibit extremely low expression levels in normal tissues. DBCO-PEG-FA can be used for click chemistry conjugation via its DBCO terminal, and thus applies to various bioconjugation and drug delivery applications .

HY-10822A

Idetrexed trisodium BGC 945 trisodium; ONX 0801 trisodium; CB 300945 trisodium		Alkynes
Idetrexed (ONX 0801) trisodium is a thymidylate synthase (TS) inhibitor with a K_i of 1.2 nM. Idetrexed trisodium can be specifically transported into α-folate receptor (α-FR)-overexpressing tumors, such as ovarian cancer .

HY-W1123936D

DBCO-PEG3400-FA DBCO-PEG3400-Folate		DBCO
DBCO-PEG-FA (DBCO-PEG-Folate) (MW 3400) is a multifunctional bioconjugation reagent, which is a copolymer of DBCO and Folic acid (FA) (HY-16637) and can target folate receptors (FR). Folate receptors are highly overexpressed on the surface of many cancer cells (such as lung cancer, nasopharyngeal cancer, ovarian cancer, etc.), but exhibit extremely low expression levels in normal tissues. DBCO-PEG-FA can be used for click chemistry conjugation via its DBCO terminal, and thus applies to various bioconjugation and drug delivery applications .

HY-W1123936H

DBCO-PEG10000-FA DBCO-PEG10000-Folate		DBCO
DBCO-PEG10000-FA (DBCO-PEG10000-Folate) is a multifunctional bioconjugation reagent, which is a copolymer of DBCO and Folic acid (FA) (HY-16637) and can target folate receptors (FR). Folate receptors are highly overexpressed on the surface of many cancer cells (such as lung cancer, nasopharyngeal cancer, ovarian cancer, etc.), but exhibit extremely low expression levels in normal tissues. DBCO-PEG-FA can be used for click chemistry conjugation via its DBCO terminal, and thus applies to various bioconjugation and drug delivery applications .

HY-W1123936E

DBCO-PEG5000-FA DBCO-PEG5000-Folate		DBCO
DBCO-PEG5000-FA (DBCO-PEG5000-Folate) is a multifunctional bioconjugation reagent, which is a copolymer of DBCO and Folic acid (FA) (HY-16637) and can target folate receptors (FR). Folate receptors are highly overexpressed on the surface of many cancer cells (such as lung cancer, nasopharyngeal cancer, ovarian cancer, etc.), but exhibit extremely low expression levels in normal tissues. DBCO-PEG-FA can be used for click chemistry conjugation via its DBCO terminal, and thus applies to various bioconjugation and drug delivery applications .

Cat. No.	상품명		Classification

HY-N0171

Beta-Sitosterol (purity>80%) Maximum Cited Publications 22 Publications Verification		Cholesterol
Beta-Sitosterol (purity≥80%) is orally active. Beta-Sitosterol exhibits multiple activities, including anti-inflammatory, anticancer, antioxidant, antimicrobial, antidiabetic, antioxidant enzyme, and analgesic. Beta-Sitosterol inhibits inflammation and impaired adipogenesis in bovine mammary epithelial cells by reducing levels of ROS, TNF-α, IL-1β, and NF-κB p65 and restoring the activity of the HIF-1α/mTOR signaling pathway. Beta-Sitosterol induces apoptosis in cancer cells through ROS-mediated mitochondrial dysregulation and p53 activation. Beta-Sitosterol exerts its anticancer effects in cancer cells by activating caspase-3, caspase-8, and caspase-9, mediating PARP inactivation, MMP loss, altered Bcl-2-Bax ratio, and cytochrome c release. Beta-Sitosterol modulates macrophage polarization and reduces rheumatoid inflammation in mice. Beta-Sitosterol inhibits tumor growth in multiple mouse cancer models. Beta-Sitosterol can be used in the research of arthritis, lung cancer, breast cancer and other cancers, diabetes, etc .

HY-145722

Apatorsen sodium 1 Publications Verification OGX-427 sodium		Antisense Oligonucleotides
Apatorsen (OGX-427) sodium is a 2'-methoxyethyl-modified antisense oligonucleotide and also a Hsp27 inhibitor. Apatorsen sodium reduces Hsp27 mRNA and protein levels, impairs stress-induced cytoprotective functions, induces cell apoptosis, inhibits tumor growth and prevents metastasis. Apatorsen sodium is applicable to research related to non-small cell lung cancer, castration-resistant prostate cancer, breast cancer, ovarian cancer and bladder cancer .

HY-151226

Glyceryl monostearate GMS		Phospholipids
Glyceryl monostearate (GMS) is a type of monoglyceride. Glyceryl monostearateGlyceryl monostearate can serve as a core lipid material for constructing solid lipid nanoparticles in the field of drug delivery. Glyceryl monostearate can be used as a gelling agent to structure liquid vegetable oils into semi-solid oleogels, so as to replace animal fat in meat products .

HY-155902

Mal-PEG5000-OH Maleimide-PEG5000-Hydroxy		Polymers
Mal-PEG5000-OH can be used as a macroinitiator to obtain amphiphilic diblock copolymers by ring-opening polymerization of LA. Nanoparticles prepared using amphiphilic block copolymers can form active drug delivery systems. Nanoparticles encapsulate Triptolide (HY-32735), which can avoid the disadvantage of Triptolide’s poor water solubility and reduce its toxicity.

HY-120967A

(2S)-OMPT		Phospholipids
(2S)-OMPT, Lysophosphatidic acid analogue, is a LPA3 G-protein-coupled receptor agonist. (2S)-OMPT selectively activates LPA3 G-protein-coupled receptor to trigger downstream cellular signaling events. (2S)-OMPT induces calcium, IL-6 release in cancer cells and activates MAPK and Akt signaling pathways. (2S)-OMPT can be used for the research of ovarian cancer .

HY-145722A

Apatorsen 1 Publications Verification OGX-427		Antisense Oligonucleotides
Apatorsen is a 2'-methoxyethyl-modified antisense oligonucleotide and also a Hsp27 inhibitor. Apatorsen reduces Hsp27 mRNA and protein levels, impairs stress-induced cytoprotective functions, induces cell apoptosis, inhibits tumor growth and prevents metastasis. Apatorsen is applicable to research related to non-small cell lung cancer, castration-resistant prostate cancer, breast cancer, ovarian cancer and bladder cancer .

HY-160062

S2.2 aptamer sodium		Aptamers
S2.2 aptamer sodium is a nucleic acid-based MUC1-binding aptamer with high affinity and low toxicity. Upon binding to its target, S2.2 aptamer sodium undergoes a conformational switch and restores fluorescence signal, serving as a targeted imaging agent for MUC1-positive cancer cells. S2.2 aptamer sodium enables targeted delivery to breast cancer cells with overexpressed MUC1. When formulated as the S2.2-PEG-MZF molecular probe, S2.2 aptamer sodium possesses the functions of T2 signal inhibition, magnetic field-induced hyperthermia and targeted magnetic resonance molecular imaging. In the S2.2-PEG-MZF/DOX nanoliposome, S2.2 aptamer sodium supports targeted thermochemotherapy, effectively inhibiting cancer cell proliferation and invasion as well as inducing apoptosis, and is widely used in studies related to breast cancer .

HY-143203

18:0-18:2 PE 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphoethanolamine		Phospholipids
18:0-18:2 PE is an important component of phosphatidylethanolamine (PE), involved in phospholipid metabolism and associated with diseases such as ovarian cancer. 18:0-18:2 PE in the hot processing process, its unsaturated fatty acids will degrade to form a variety of odor active compounds. 18:0-18:2 PE is mainly used in the field of food science to improve the flavor of aquatic products, as well as medical research on diseases related to phospholipid metabolism .

HY-155902A

Mal-PEG2000-OH Maleimide-PEG2000-Hydroxy		Polymers
Mal-PEG2000-OH can be used as a macroinitiator to obtain amphiphilic diblock copolymers by ring-opening polymerization of LA. Nanoparticles prepared using amphiphilic block copolymers can form active drug delivery systems. Nanoparticles encapsulate Triptolide (HY-32735), which can avoid the disadvantage of Triptolide’s poor water solubility and reduce its toxicity.

HY-W783254

C18 LPA PA(18:0e/0:0)		Phospholipids
C18 LPA (PA(18:0e/0:0)) is a water-soluble phospholipid that functions as a signaling molecule, influencing various cellular responses through G protein-coupled receptors (GPCRs). It is known to promote smooth muscle contraction, cytoskeletal rearrangement, and chemotaxis, while also playing a role in neurotransmitter release, cell proliferation, platelet aggregation, and Ca2+ mobilization. Elevated levels of C18 LPA in human plasma are associated with ovarian cancer and atherosclerosis, suggesting its potential as a biomarker for ovarian cancer.

HY-155902B

Mal-PEG1000-OH Maleimide-PEG1000-Hydroxy		Polymers
Mal-PEG1000-OH was used as a macroinitiator to obtain amphiphilic diblock copolymers by ring-opening polymerization of LA. Nanoparticles prepared using amphiphilic block copolymers can form active drug delivery systems. Nanoparticles encapsulate Triptolide (HY-32735), which can avoid the disadvantage of Triptolide’s poor water solubility and reduce its toxicity.

HY-177811

HE4 aptamer sodium		Aptamers
HE4 aptamer sodium is a DNA aptamer with affinity for the ovarian cancer biomarker HE4.

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

ovarian

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

GMP Molecules

Natural
Products